Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain

被引:18
|
作者
Salleras, L [1 ]
Domínguez, A [1 ]
Cardeñosa, N [1 ]
机构
[1] Directorate Publ Hlth, Dept Hlth & Social Secur, E-08028 Barcelona, Spain
关键词
mass vaccination; serogroup C meningococcal disease; conjugated vaccine; case fatality rate; incidence;
D O I
10.1016/S0264-410X(02)00589-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
During the fourth quarter of 1997, a vaccination campaign using the meningococcal C polysaccharide vaccine was carried out in 14 autonomous regions of Spain. The remaining three regions did not participate. In the last quarter of the year 2000, a mass vaccination campaign using the meningococcal C conjugated vaccine was carried out in all regions. In the year 2001 the incidence decreased in all regions, although the decrease was greater in regions that did not vaccinate in 1997. In contrast, case fatality rates did not decrease. During 200 1, the incidence rate of meningococcal C disease was still lower (0.32 per 100,000 persons-year) in the regions that vaccinated in 1997 with the polysaccharide vaccine than in those that did not (0.64 per 100,000 persons-year). (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:725 / 728
页数:4
相关论文
共 50 条
  • [1] Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination
    Perez-Breva, Lina
    Abad-Torreblanca, Raquel
    Angel Martinez-Beneito, Miguel
    Puig-Barbera, Joan
    Aleman-Sanchez, Sara
    Morant-Talamante, Nuria
    Sastre-Canton, Macrina
    Vazquez-Moreno, Julio A.
    Diez-Domingo, Javier
    [J]. VACCINE, 2017, 35 (22) : 2949 - 2954
  • [2] Control of serogroup C meningococcal disease by mass vaccination in Catalonia (Spain)
    Salleras, L
    Domínguez, A
    Prats, G
    [J]. VACCINE, 1999, 17 : S56 - S60
  • [3] Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine
    Salleras, L
    Domínguez, A
    Cardeñosa, N
    [J]. VACCINE, 2003, 21 (7-8) : 729 - 733
  • [4] The impact of meningococcal serogroup C conjugate vaccine in Scotland
    Mooney, JD
    Christie, P
    Robertson, C
    Clarke, SC
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (03) : 349 - 356
  • [5] Memory immune response generated in Cercopithecusaethiops against meningococcal polysaccharide serogroup C conjugate vaccine
    Carmenate, T
    Guirola, M
    Alvarez, A
    Canaán, L
    González, S
    Caballero, E
    Menéndez, T
    Guillén, G
    [J]. FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2005, 43 (02): : 133 - 140
  • [6] Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination
    Trotter, CL
    Gay, NJ
    Edmunds, WJ
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2005, 162 (01) : 89 - 100
  • [7] Meningococcal serogroup C conjugate vaccine
    Lakshman, R
    Finn, A
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (01) : 87 - 96
  • [8] Impact of serogroup A meningococcal conjugate vaccine for Africa
    Stuart, James M.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (05) : 1116 - 1117
  • [10] Epidemiological pattern of meningococcal disease in Valencia, Spain.: Impact of a mass immunization campaign with meningococcal C polysaccharide vaccine
    Pereiró, I
    Díez-Domingo, J
    Morant, A
    Gimeno, C
    Lerma, M
    San-Martín, M
    González, A
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2001, 33 (08) : 581 - 584